Corporate
Ropack, l’entreprise montréalaise spécialisée en emballage pharmaceutique, choisit SOLABS pour la gestion de ses documents
Montréal, le 16 avril 2008 -- SOLABS, un des leaders canadiens en conception de solutions pour la gestion de documents sans papier, a annoncé aujourd’hui que Ropack, une entreprise spécialisée dans l’emballage de produits pharmaceutiques, a opté pour le système de gestion de la qualité SOLABS GxP afin d’optimiser sa gestion de documents et ses processus de travail.
SOLABS joins SAFE BIOPHARMA's vendor partner program
SOLABS has joined SAFE BioPharma Association as a Vendor-Partner. SOLABS will be adapting its software to enable utilization of the SAFE™ digital signature standard, which provides a secure, enforceable and regulatory compliant way to verify the identity of parties in business-to-business and business-to regulator electronic transactions.
"Our objective was to streamline and automate a number of key processes, such as protocols, study reports, quality processes and training records" said Ms Nadine Bouchard, Director of Compliance and Associate, Regulatory Affairs. SOLABS was able to bring to us a schedule that was consistent with our objectives. Their knowledge of the GxP environment meant that we could start work almost immediately". Sandoz Canada chooses SOLABS
"This is a major development for SOLABS", said Richard Fecteau, President and CEO. "Sandoz Canada is the internationally renowned Sandoz Centre of Excellence for injectable products since it has unique processes that require specific expertise. SOLABS GxP will be used initially to handle SOPs, IT documentation, and the change control process. SOLABS GMP is also capable of processing batch records, recipes and CAPA but these functionalities are not presently under scope with Sandoz Canada." Merck Abandons Paper
"Getting rid of paper, for the Q.A. Manager, is like sky diving for people who fear heights!" commented Michael Meighu, VP GMP Practice. But, this is exactly what Debbi Treadwell and Joanna Hills at Merck Sharp and Dohme's plant in Ponders End, UK have done. Tea party in Boston? SOLABS presents how Biotechnology companies can gain added-value.
On April 4th 2006, SOLABS presented a technology showcase seminar at Bio-IT Life Sciences Conference and EXPO in Boston, MA. The hour-long presentation explained how biotechnology companies, mainly involved in R&D, could add significant value to their businesses by shortening the time to market of their new drugs and devices. Mr Philippe Gaudreau (SOLABS COO) and Dr. John Lawson (SOLABS Marketing) shared the presentation to inform attendees on how electronic regulated process and documentation management could, rather be an on-cost imposition, release added-value that could help them to get their products to market more quickly. Although almost immediate ROI gains can be made by improving the workflow of regulated documents, strategic benefits give much larger returns but are more difficult to quantify.
A copy of this presentation is available under Resources.
BACK from Vienna, SOLABS to host a breakfast seminar to share latest practice trends
On November 24th 2005 SOLABS will be hosting a breakfast seminar at the Holiday Inn in Pointe-Claire, Québec. The breakfast aims at sharing our findings and discussions with regard to with the latest global challenges around document management. We will also communicate a summary of our workshop "From Passive Compliance to Strategic Advantage" presented in Vienna. Presenters will include Dr. John Lawson (SOLABS Marketing) and Mr. Dany Salvail (lead scientist of IPS Thérapeutique) who will explain how improving workflow management in a GLP environment has become a competitive advantage towards similar international players. An open forum will be chaired by Mr Richard Fecteau (SOLABS Chairman) to listen to views and direct questions.
SOLABS goes to Vienna
On 4th October 2005 SOLABS will be presenting a workshop at the World Drug Manufacturers' Summit in Vienna, Austria. The workshop, "From Passive Compliance to Strategic Advantage" aims to break the paradigm that suggests compliance to be merely a cost driver. If used strategically effective and efficient compliance could open up new competitive scenarios that protect the best performers from less progressive competitors. Presenters will include Dr. John Lawson (SOLABS Marketing) and Mr. Michael Meighu (SOLABS GMP Practice) together with Ms. Joanna Hills of Merck Sharp & Dohme, UK who will show how they tackled the issue of creating 'paperless' document and process management. An open forum will be chaired by Mr Richard Fecteau (SOLABS Chairman) to listen to views and direct questions.
Back to top
Alibaba™ name to be dropped
The name Alibaba™ has been used on the SOLABS software platform since the company's inception in 1999. The decision to drop the name has, therefore, been a difficult one. Mr. Philippe Gaudreau (President and a founder of SOLABS) commented, "The name Alibaba™ was given to the original technology platform but its continued use suggested that the company is merely a vendor of software. This does not rightfully describe what we do. SOLABS has a service-based model where best GxP practices can be implemented within a robust IT framework. We can do this all the way along the drug development process from GLP to GCP to GMP. We are not just software vendors!" The company has decided to re-badge its augmented services - SOLABS GMP, SOLABS GLP and SOLABS GCP to be better aligned to the content of the solution and not the IT platform.
Back to top
Chairman Mr. Richard Fecteau actively joins SOLABS'
June 2005
Richard Fecteau, former head of Invensys' US$20m per year Pharma validation and automation group, has been shareholder Chairman of SOLABS since 2000. As coach and mentor to SOLABS' founders his input was invaluable in securing profitable growth. Richard now takes an operational role in the business which is on the brink of rapid growth.
For further information on Mr. Fecteau' profile, click here.
Back to top
John Lawson takes on the mandate of communicating SOLABS' value proposition
April 2005
Who are you Mr. Lawson? "Qualified as a pharmacist and doctor of business administration, I have spent 30 years working in, and around, the pharmaceutical industry. In the last 10 years I have held the positions of VP Global Life Sciences Marketing with STERIS Corporation (handling a $250m product portfolio) and VP Customer Development with IMS Health in Canada. I have joined SOLABS to guide their marketing strategy in the GxP arena."
John Lawson, Doctor of Business Administration (Marketing)
Back to top
Merck Sharp & Dohme, a global research-based pharmaceutical company, selects SOLABS
March 2005
MSD's Ponders End facility is a key manufacturing site for the European market. According to Joanna Hills, Merck's site documentation specialist, they were managing lots of hard copies and it was very time-consuming and costly. She explained that their choice of the SOLABS technology and service offering was made because of SOLABS' plentiful pharmaceutical industry experience - a rarity, she believed, among other generic content management system vendors.
Using Alibaba™ yielded more than a 95 percent reduction of cycle time for physical workflow. And Alibaba™ entirely eliminated the labor costs associated with managing hard copies. This reduction corresponds to about a 60 to 80 percent overall reduction for cGMP document management costs.
Commenting upon the new venture Philippe Gaudreau, SOLABS' founder and CEO, said, "Merck's decision is viewed as a significant vote of confidence in the quality and performance of the SOLABS software and service offering. There are other organizations that produce generic document management software but few understand the full requirements of GxP compliance. The SOLABS team has both the experience and dedicated focus on this business segment. Our proven global implementation and support capability, we feel, will be a strong factor facilitating the roll-out of our solution for multinational companies."
Back to top
VITA Health Products, a Leiner company, selects SOLABS
February 2005
VITA Health Products, part of the second largest manufacturer of private label OTC pharmaceuticals in the U.S. (Leiner), has chosen SOLABS' solutions and services to help reduce its compliance documentation risks and costs.
"Not only will Alibaba™ drastically reduce the efforts required to keep our documentation up to date, but it will also eliminate risks that occur with paper systems."
Carlson Teakle, Vice-President I.T., VITA Health Products
Back to top